Search research articles
Contact Us
Filters
Showing results (41-50 of 62) with videos related to
Page
of 7
Sort By:
European Urology Oncology
|
March 15, 2022
Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial
Johannes Alfred Witjes, Matthew D Galsky, Jürgen E Gschwend, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 10, 2023
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
Albert Oriol, Meletios Dimopoulos, Fredrik Schjesvold, et al.
Annals of Hematology
|
October 10, 2025
Impact of clinical response and treatment tolerability on HRQoL in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib
Ajibade Ashaye, Ling Shi, Ibrahim Aldoss, et al.
Cancer Medicine
|
April 1, 2025
Quality-Adjusted Time Without Symptoms of Disease or Toxicity (Q-TWiST) in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Comparison of Ponatinib Versus Imatinib
Ajibade Ashaye, Ling Shi, Ibrahim Aldoss, et al.
European Journal of Haematology
|
March 20, 2026
Patient-Reported Outcomes With Luspatercept Through 5 Years of Treatment in Patients With Non-Transfusion-Dependent β-Thalassemia Treated in the BEYOND Trial
Khaled M Musallam, Maria Domenica Cappellini, Antonis Kattamis, et al.
BMJ Open
|
March 22, 2023
Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia
Ali T Taher, Khaled M Musallam, Vip Viprakasit, et al.
Frontiers in Oncology
|
February 24, 2025
Psychometric properties and meaningful change thresholds for the QOL-E instrument in patients with myelodysplastic neoplasms
Esther Natalie Oliva, Shien Guo, Jennifer Lord-Bessen, et al.
Leukemia
|
April 16, 2025
Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial
Ajibade Ashaye, Ling Shi, Ibrahim Aldoss, et al.
BMJ Open
|
November 14, 2024
Identifying thresholds for meaningful improvements in NTDT-PRO scores to support conclusions about treatment benefit in clinical studies of patients with non-transfusion-dependent beta-thalassaemia: analysis of pooled data from a phase 2, double-blind, placebo-controlled, randomised trial
Ali T Taher, Khaled M Musallam, Vip Viprakasit, et al.
Hemasphere
|
May 10, 2021
Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial
Ruben A Mesa, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 62) with videos related to
Sort By:
Page
of 7
European Urology Oncology
|
March 15, 2022
Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial
Johannes Alfred Witjes, Matthew D Galsky, Jürgen E Gschwend, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 10, 2023
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
Albert Oriol, Meletios Dimopoulos, Fredrik Schjesvold, et al.
Annals of Hematology
|
October 10, 2025
Impact of clinical response and treatment tolerability on HRQoL in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib
Ajibade Ashaye, Ling Shi, Ibrahim Aldoss, et al.
Cancer Medicine
|
April 1, 2025
Quality-Adjusted Time Without Symptoms of Disease or Toxicity (Q-TWiST) in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Comparison of Ponatinib Versus Imatinib
Ajibade Ashaye, Ling Shi, Ibrahim Aldoss, et al.
European Journal of Haematology
|
March 20, 2026
Patient-Reported Outcomes With Luspatercept Through 5 Years of Treatment in Patients With Non-Transfusion-Dependent β-Thalassemia Treated in the BEYOND Trial
Khaled M Musallam, Maria Domenica Cappellini, Antonis Kattamis, et al.
BMJ Open
|
March 22, 2023
Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia
Ali T Taher, Khaled M Musallam, Vip Viprakasit, et al.
Frontiers in Oncology
|
February 24, 2025
Psychometric properties and meaningful change thresholds for the QOL-E instrument in patients with myelodysplastic neoplasms
Esther Natalie Oliva, Shien Guo, Jennifer Lord-Bessen, et al.
Leukemia
|
April 16, 2025
Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial
Ajibade Ashaye, Ling Shi, Ibrahim Aldoss, et al.
BMJ Open
|
November 14, 2024
Identifying thresholds for meaningful improvements in NTDT-PRO scores to support conclusions about treatment benefit in clinical studies of patients with non-transfusion-dependent beta-thalassaemia: analysis of pooled data from a phase 2, double-blind, placebo-controlled, randomised trial
Ali T Taher, Khaled M Musallam, Vip Viprakasit, et al.
Hemasphere
|
May 10, 2021
Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial
Ruben A Mesa, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Page
of 7